
Ying-Chun Shen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1641955/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early alphaâ€fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 4590-4596.	4.1	154
2	Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1986-1990.	2.5	130
3	Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology, 2010, 52, 889-894.	3.7	125
4	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 126-131.	3.7	124
5	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology, 2011, 55, 858-865.	3.7	114
6	Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1807-1814.	2.5	103
7	Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2010, 70, 9309-9318.	0.9	76
8	Difference in the Incidence Trend of Nasopharyngeal and Oropharyngeal Carcinomas in Taiwan: Implication from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 856-861.	2.5	65
9	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Journal of Gastroenterology, 2010, 45, 794-807.	5.1	61
10	Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2013, 2, 345-364.	7.7	58
11	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	7.7	57
12	Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials, 2010, 31, 55-61.	1.8	46
13	Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma. Oncology, 2011, 81, 372-380.	1.9	46
14	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases, 2018, 21, 113-125.	3.9	46
15	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 489-497.	3.7	38
16	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 5820-5828.	7.0	35
17	A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression. Oncology, 2012, 82, 275-289.	1.9	35
18	Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sciences, 2010, 86, 199-206	4.3	33

YING-CHUN SHEN

#	Article	IF	CITATIONS
19	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	1.9	28
20	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
21	Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 417-423.	2.5	24
22	Gastric Bleeding Due to Graft-vs-Host Disease. American Journal of Clinical Pathology, 2004, 122, 919-925.	0.7	22
23	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. Oncology, 2011, 81, 98-103.	1.9	19
24	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer, 2012, 15, 265-280.	5.3	17
25	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma, 2014, 1, 85.	3.7	17
26	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	3.7	17
27	Author's reply: Vitamin A and gastric cancer risk. Gastric Cancer, 2012, 15, 344-344.	5.3	16
28	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285.	3.7	14
29	Epithelial Aryl Hydrocarbon Receptor Protects From Mucus Production by Inhibiting ROS-Triggered NLRP3 Inflammasome in Asthma. Frontiers in Immunology, 2021, 12, 767508.	4.8	14
30	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Review of Clinical Pharmacology, 2009, 2, 129-136.	3.1	11
31	Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 643-653.	1.9	11
32	Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation. JCI Insight, 2022, , .	5.0	11
33	MCC950 Ameliorates Acute Liver Injury Through Modulating Macrophage Polarization and Myeloid-Derived Suppressor Cells Function. Frontiers in Medicine, 2021, 8, 752223.	2.6	6
34	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	3.0	5
35	Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	1.7	3
36	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anti-Cancer Drugs, 2005, 16, 739-742.	1.4	2

#	Article	IF	CITATIONS
37	Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study. , 2021, , .		2
38	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers, 2021, 13, 5142.	3.7	2
39	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2017, 35, e15656-e15656.	1.6	1
40	Expression of human leukocyte antigen-a and b2-microglobulin in prostate cancer Journal of Clinical Oncology, 2019, 37, e16550-e16550.	1.6	1
41	Effects of prophylactic high and low doses of corticosteroid on the efficacy of immune checkpoint blockade in murine hepatocellular carcinoma models Journal of Clinical Oncology, 2022, 40, e14596-e14596.	1.6	1